Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?-Reference-Cited by-同舟云学术

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

Published:2020-07-02 Issue:1 Volume:136 Page:137-139
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Frigault Matthew J.¹,Nikiforow Sarah²,Mansour Michael K.³^ORCID,Hu Zhen-Huan⁴,Horowitz Mary M.⁴⁵,Riches Marcie L.⁶^ORCID,Hematti Peiman⁷,Turtle Cameron J.⁸,Zhang Mei-Jie⁴,Perales Miguel-Angel⁹,Pasquini Marcelo C.⁴⁵^ORCID

Affiliation:

1. Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, MA;

2. Division of Hematologic Malignancies, Department of Medicine, Dana-Farber Cancer Institute, Boston, MA;

3. Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA;

4. Center for International Blood and Marrow Transplant Research and

5. Blood and Marrow Transplant and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI;

6. Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC;

7. Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin, Madison, WI;

8. Department of Medicine, University of Washington, Seattle, WA; and

9. Adult Blood and Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/136/1/137/1747535/bloodbld2020006216.pdf

Reference21 articles.

1. Covid-19 in critically ill patients in the Seattle region - case series;Bhatraju;N Engl J Med,2020

2. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study;Zhou;Lancet,2020

3. State of the art in CAR T cell therapy for CD19+ B cell malignancies;Frigault;J Clin Invest,2020

4. Clinical and immunologic features in severe and moderate coronavirus disease 2019;Chen;J Clin Invest,2020

5. Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis [published online ahead of print 15 April 2020];Zhu;J Med Virol

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of infectious complications among CAR T- cell therapy recipients;Frontiers in Oncology;2024-07-03

2. Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma;Frontiers in Oncology;2024-06-11

3. Current understanding and management of CAR T cell-associated toxicities;Nature Reviews Clinical Oncology;2024-05-20

4. Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia;Clinical and Experimental Medicine;2024-04-25

5. Outcome of Tocilizumab Treatment in Febrile Neutropenic Children with Severe Sepsis/Septic Shock in a Single-Center Retrospective Case Series;Cancers;2024-04-16